212 related articles for article (PubMed ID: 17024116)
21. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.
Parry-Jones N; Matutes E; Morilla R; Brito-Babapulle V; Wotherspoon A; Swansbury GJ; Catovsky D
Br J Haematol; 2007 Apr; 137(2):117-24. PubMed ID: 17391491
[TBL] [Abstract][Full Text] [Related]
22. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
23. Deletion of the retinoblastoma gene in multiple myeloma.
Dao DD; Sawyer JR; Epstein J; Hoover RG; Barlogie B; Tricot G
Leukemia; 1994 Aug; 8(8):1280-4. PubMed ID: 8057662
[TBL] [Abstract][Full Text] [Related]
24. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
[TBL] [Abstract][Full Text] [Related]
25. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
26. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Krämer A; Schultheis B; Bergmann J; Willer A; Hegenbart U; Ho AD; Goldschmidt H; Hehlmann R
Leukemia; 2002 Sep; 16(9):1844-51. PubMed ID: 12200702
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
28. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
de Larrea CF; Navarro A; Tejero R; Tovar N; Díaz T; Cibeira MT; Rosiñol L; Ferrer G; Rovira M; Rozman M; Monzó M; Bladé J
Clin Cancer Res; 2012 Jul; 18(13):3697-704. PubMed ID: 22539802
[TBL] [Abstract][Full Text] [Related]
29. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
[TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
32. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
33. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
[TBL] [Abstract][Full Text] [Related]
34. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
35. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.
Filipits M; Pohl G; Stranzl T; Kaufmann H; Ackermann J; Gisslinger H; Greinix H; Chott A; Drach J
Clin Cancer Res; 2003 Feb; 9(2):820-6. PubMed ID: 12576455
[TBL] [Abstract][Full Text] [Related]
36. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
37. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
Chang H; Sloan S; Li D; Keith Stewart A
Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
[TBL] [Abstract][Full Text] [Related]
38. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
39. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma.
Ross FM; Ibrahim AH; Vilain-Holmes A; Winfield MO; Chiecchio L; Protheroe RK; Strike P; Gunasekera JL; Jones A; Harrison CJ; Morgan GJ; Cross NC;
Leukemia; 2005 Sep; 19(9):1634-42. PubMed ID: 15990862
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Moreau P; Attal M; Garban F; Hulin C; Facon T; Marit G; Michallet M; Doyen C; Leyvraz S; Mohty M; Wetterwald M; Mathiot C; Caillot D; Berthou C; Benboubker L; Garderet L; Chaleteix C; Traullé C; Fuzibet JG; Jaubert J; Lamy T; Casassus P; Dib M; Kolb B; Dorvaux V; Grosbois B; Yakoub-Agha I; Harousseau JL; Avet-Loiseau H; ;
Leukemia; 2007 Sep; 21(9):2020-4. PubMed ID: 17625611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
